Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.

Adult Antibiotics, Antitubercular / pharmacology Child Cohort Studies Democratic Republic of the Congo / epidemiology Drug Resistance, Bacterial Humans Mycobacterium tuberculosis / drug effects Prevalence Retrospective Studies Rifampin / pharmacology Sputum / microbiology Treatment Outcome Tuberculosis, Multidrug-Resistant / drug therapy Tuberculosis, Pulmonary / drug therapy
eastern DR Congo multidrug-resistant TB predictors prevalence treatment outcomes

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
27 09 2019
Historique:
received: 11 10 2018
accepted: 20 12 2018
pubmed: 14 2 2019
medline: 15 9 2020
entrez: 14 2 2019
Statut: ppublish

Résumé

Multidrug-resistant tuberculosis (MDR-TB) jeopardizes global TB control. The prevalence and predictors of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and shortened regimens have not been assessed in post-conflict regions, such as the South Kivu province in the eastern Democratic Republic of the Congo (DRC). We aimed to fill this knowledge gap and to inform the DRC National TB Program. of adults and children evaluated for pulmonary TB by sputum smear microscopy and Xpert MTB/RIF (Xpert) from February 2012 to June 2017. Multivariable logistic regression, Kaplan-Meier estimates, and multivariable Cox regression were used to assess independent predictors of RR-TB and treatment failure/death. Of 1535 patients Xpert-positive for TB, 11% had RR-TB. Independent predictors of RR-TB were a positive sputum smear (adjusted odds ratio [aOR] 2.42, 95% confidence interval [CI] 1.63-3.59), retreatment of TB (aOR 4.92, 95% CI 2.31-10.45), and one or more prior TB episodes (aOR 1.77 per episode, 95% CI 1.01-3.10). Over 45% of RR-TB patients had no prior TB history or treatment. The median time from Xpert diagnosis to RR-TB treatment initiation was 12 days (interquartile range 3-60.2). Cures were achieved in 30/36 (83%) and 84/114 (74%) of patients on 9- vs 20/24-month MDR-TB regimens, respectively (P = .06). Predictors of treatment failure/death were the absence of directly observed therapy (DOT; adjusted hazard ratio [aHR] 2.77, 95% CI 1.2-6.66) and any serious adverse drug event (aHR 4.28, 95% CI 1.88-9.71). Favorable RR-TB cure rates are achievable in this post-conflict setting with a high RR-TB prevalence. An expanded Xpert scale-up; the prompt initiation of shorter, safer, highly effective MDR-TB regimens; and treatment adherence support are critically needed to optimize outcomes.

Sections du résumé

BACKGROUND
Multidrug-resistant tuberculosis (MDR-TB) jeopardizes global TB control. The prevalence and predictors of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and shortened regimens have not been assessed in post-conflict regions, such as the South Kivu province in the eastern Democratic Republic of the Congo (DRC). We aimed to fill this knowledge gap and to inform the DRC National TB Program.
METHODS
of adults and children evaluated for pulmonary TB by sputum smear microscopy and Xpert MTB/RIF (Xpert) from February 2012 to June 2017. Multivariable logistic regression, Kaplan-Meier estimates, and multivariable Cox regression were used to assess independent predictors of RR-TB and treatment failure/death.
RESULTS
Of 1535 patients Xpert-positive for TB, 11% had RR-TB. Independent predictors of RR-TB were a positive sputum smear (adjusted odds ratio [aOR] 2.42, 95% confidence interval [CI] 1.63-3.59), retreatment of TB (aOR 4.92, 95% CI 2.31-10.45), and one or more prior TB episodes (aOR 1.77 per episode, 95% CI 1.01-3.10). Over 45% of RR-TB patients had no prior TB history or treatment. The median time from Xpert diagnosis to RR-TB treatment initiation was 12 days (interquartile range 3-60.2). Cures were achieved in 30/36 (83%) and 84/114 (74%) of patients on 9- vs 20/24-month MDR-TB regimens, respectively (P = .06). Predictors of treatment failure/death were the absence of directly observed therapy (DOT; adjusted hazard ratio [aHR] 2.77, 95% CI 1.2-6.66) and any serious adverse drug event (aHR 4.28, 95% CI 1.88-9.71).
CONCLUSIONS
Favorable RR-TB cure rates are achievable in this post-conflict setting with a high RR-TB prevalence. An expanded Xpert scale-up; the prompt initiation of shorter, safer, highly effective MDR-TB regimens; and treatment adherence support are critically needed to optimize outcomes.

Identifiants

DOI: 10.1093/cid/ciy1105 PMID: 30759187 PMC: PMC6763636
pubmed: 30759187
pii: 5316466
doi: 10.1093/cid/ciy1105
pmc: PMC6763636
doi:

Substances chimiques

Antibiotics, Antitubercular 0
Rifampin VJT6J7R4TR

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1278-1287

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI069521
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010340
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Int J Tuberc Lung Dis. 2016 Feb;20(2):240-6
pubmed: 26792478
Am J Trop Med Hyg. 2014 Oct;91(4):715-21
pubmed: 25071001
Clin Infect Dis. 2017 Oct 1;65(7):1206-1211
pubmed: 29554229
Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S24-30
pubmed: 12516027
N Engl J Med. 2010 Sep 9;363(11):1005-15
pubmed: 20825313
PLoS One. 2014 Apr 14;9(4):e94618
pubmed: 24732233
Respirology. 2018 Jan;23(1):36-45
pubmed: 28850767
Eur Respir Rev. 2016 Mar;25(139):29-35
pubmed: 26929418
PLoS One. 2014 Jan 08;9(1):e82235
pubmed: 24416139
Int J Tuberc Lung Dis. 2009 Oct;13(10):1274-80
pubmed: 19793433
Bull World Health Organ. 2018 Jul 1;96(7):471-483
pubmed: 29962550
J Clin Microbiol. 2011 May;49(5):1772-6
pubmed: 21411592
Int J Tuberc Lung Dis. 2018 Apr 1;22(4):407-412
pubmed: 29562988
Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92
pubmed: 20442432
N Engl J Med. 2017 Jan 19;376(3):243-253
pubmed: 28099825
N Engl J Med. 2012 Jun 7;366(23):2151-60
pubmed: 22670901
Infect Drug Resist. 2017 Mar 13;10:91-96
pubmed: 28331350
Emerg Infect Dis. 2012 Aug;18(8):1342-5
pubmed: 22840848
Int J Tuberc Lung Dis. 2015 May;19(5):517-24
pubmed: 25868018
BMC Infect Dis. 2014 Jan 02;14:2
pubmed: 24383553
N Engl J Med. 2014 Aug 21;371(8):723-32
pubmed: 25140958
PLoS Med. 2012;9(8):e1001300
pubmed: 22952439
Int J Tuberc Lung Dis. 2013 Apr;17(4):526-31
pubmed: 23485387
Lancet Respir Med. 2015 Dec;3(12):963-72
pubmed: 26597127
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25
pubmed: 29149917
Science. 2006 Jun 30;312(5782):1944-6
pubmed: 16809538
Lancet. 2011 Apr 30;377(9776):1495-505
pubmed: 21507477
Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7
pubmed: 25216831
BMC Infect Dis. 2017 Jan 6;17(1):36
pubmed: 28061832
PLoS One. 2009;4(5):e5561
pubmed: 19440304
Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94
pubmed: 25216832
Int J Tuberc Lung Dis. 2012 Aug;16(8):1066-8
pubmed: 22565108
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751411
Int J Tuberc Lung Dis. 2015 Aug;19(8):969-78
pubmed: 26162364

Auteurs

André N H Bulabula (ANH)

Department of Global Health, Division of Health Systems and Public Health, Unit for Infection Prevention and Control, Faculty of Medicine and Health Sciences, Stellenbosch University.
Infection Control Africa Network, Cape Town, South Africa.

Jenna A Nelson (JA)

Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pennsylvania.

Eric M Musafiri (EM)

National Tuberculosis Program, Provincial Leprosy and Tuberculosis Coordination, South Kivu Branch, Bukavu, Democratic Republic of the Congo.

Rhoderick Machekano (R)

Department of Global Health, Center for Evidence-Based Health Care, Biostatistics Unit, Faculty of Medicine and Health Sciences, Cape Town, South Africa.

Nadia A Sam-Agudu (NA)

International Research Center of Excellence and Pediatric and Adolescent Human Immunodeficiency Virus Unit, Institute of Human Virology Nigeria, Abuja.
Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine, Baltimore.

Andreas H Diacon (AH)

Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Maunank Shah (M)

Center for Tuberculosis Research & Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland.

Jacob Creswell (J)

Stop TB Partnership, TB REACH Initiative, Geneva, Switzerland.

Grant Theron (G)

South African Department of Science and Technology and the National Research Foundation, Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Robin M Warren (RM)

South African Department of Science and Technology and the National Research Foundation, Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Karen R Jacobson (KR)

Department of Medicine, Division of Infectious Diseases, Boston University School of Medicine, Massachusetts.

Jean-Paul Chirambiza (JP)

National Tuberculosis Program, Provincial Leprosy and Tuberculosis Coordination, South Kivu Branch, Bukavu, Democratic Republic of the Congo.

Dieudonné Kalumuna (D)

National Tuberculosis Program, Provincial Leprosy and Tuberculosis Coordination, South Kivu Branch, Bukavu, Democratic Republic of the Congo.

Bertin C Bisimwa (BC)

Biomedical Laboratory Professor A. Z. Lurhuma, Mycobacterium Unit, Université Catholique de Bukavu, Democratic Republic of the Congo.

Patrick D M C Katoto (PDMC)

Centre for Environment and Health, Department of Public Health and Primary Care, Laboratory of Pulmonology, The Katholieke Universiteit Leuven, Belgium.
Department of Internal Medicine, Faculty of Medicine, Catholic University of Bukavu.

Michel K Kaswa (MK)

National Tuberculosis Program, Provincial Leprosy and Tuberculosis Coordination, South Kivu Branch, Bukavu, Democratic Republic of the Congo.

Freddy M Birembano (FM)

National Tuberculosis Program, Provincial Leprosy and Tuberculosis Coordination, South Kivu Branch, Bukavu, Democratic Republic of the Congo.

Liliane Kitete (L)

The Union Against Tuberculosis and Lung Diseases, Challenge Tuberculosis Initiative, Bukavu, Democratic Republic of the Congo.

Martin P Grobusch (MP)

Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, The Academic Medical Center, The Netherlands.

Zacharie M Kashongwe (ZM)

Department of Medicine, University Hospital of Kinshasa, Democratic Republic of the Congo.

Jean B Nachega (JB)

Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pennsylvania.
Department of Medicine and Center for Infectious Diseases, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
International Centre for Advanced Research and Training, Panzi, Bukavu, Democratic Republic of the Congo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › Antibiotiques antituberculeux › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Personnes › Tranches d'âge › Enfant › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Régions géographiques › Afrique › Afrique subsaharienne › Afrique centrale › République démocratique du Congo › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance bactérienne aux médicaments › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifampicine › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Liquides et sécrétions biologiques › Sécrétions corporelles › Expectoration › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Tuberculose multirésistante › Prevalence, Predictors, and Successful...
Recherchemedicale.com › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Tuberculose pulmonaire › Prevalence, Predictors, and Successful...